Cardiology

Your Article Summary

See Latest Articles

Coronary heart disease benefits from blood pressure and lipid-lowering
International Journal of Cardiology, 06/15/09

Sever PS et al. – Coronary heart disease (CHD) benefits associated with blood pressure (BP) and lipid lowering were larger than predicted by previous observational and trial data. Compared with pre-trial treatment, treating an estimated 55 pts with the amlodipine-based regimen and atorvastatin would prevent 1 CHD event per year.

• Report of analyses on combined benefits of atorvastatin and an amlodipine-based regimen for CHD events in hypertensive pts in Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
• Randomization of 19,342 hypertensive pts to either an amlodipine or atenolol-based regimen in ASCOT Blood Pressure-Lowering Arm (BPLA)
• Further randomization 10,305 subjects with total cholesterol ≤6.5 mmol/L to atorvastatin 10 mg or placebo in Lipid-Lowering Arm (LLA)
• Estimates of CHD risk at baseline based on Framingham algorithm compared with observed and predicted event rates throughout ASCOT-LLA

• Estimated baseline Framingham risk of CHD events: 22.8 / 1000 pt yrs
• After 3.3 yrs, when LLA stopped, actual CHD event rate was 4.8 / 1000 pt years -- 79% reduction in pts assigned amlodipine-based treatment and atorvastatin

Related Articles

See all related articles

Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization
Journal of Vascular Surgery, 10/21/09    Relevance Score: 84%

Total cholesterol and LDL levels decrease before rheumatoid arthritis
Annals of Rheumatic Diseases, 11/10/09    Relevance Score: 82%

Lipid-Lowering Therapy for the Primary Prevention of Cardiovascular Disease in the Elderly: Opportunities and Challenges
Drugs & Aging, 10/26/09    Relevance Score: 80%

Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006
Journal of Hypertension, 10/23/09    Relevance Score: 80%

ADAM17_i33708A>G polymorphism interacts with dietary n-6 polyunsaturated fatty acids to modulate obesity risk in the Genetics of Lipid Lowering Drugs and Diet Network study
Nutrition, Metabolism & Cardiovascular Diseases, 10/15/09    Relevance Score: 80%

Today in Atherosclerosis/Lipids...keeping you current

Receive free subspecialty "5-minute updates" via email

Smoking intensity and lipoprotein abnormalities in active smokers
Journal of Clinical Lipidology, 12/18/09

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia
Current Medical Research and Opinion, 12/18/09

Walking Speed and Subclinical Atherosclerosis in Healthy Older Adults: The Whitehall Ii Study
Heart, 12/18/09

 See all of Atherosclerosis/Lipids

Today in Coronary Artery Disease...keeping you current

Receive free subspecialty "5-minute updates" via email

Apolipoprotein E gene polymorphisms and serum cholesterol in healthy Irish adults: a proposed genetic marker for coronary artery disease risk
Irish Journal of Medical Science, 12/18/09

Influence of Genetic Polymorphism in Matrix Metalloproteinase-3 on Extent of Coronary Atherosclerosis and Risk of Coronary Artery Stenosis
Archives of Medical Research, 12/18/09

High Prevalence of Coronary Heart Disease in Type 2 Diabetic Patients with Non-alcoholic Fatty Liver Disease
Archives of Medical Research, 12/18/09

 See all of Coronary Artery Disease

Today in Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

How do providers assess antihypertensive medication adherence in medical encounters?
Journal of General Internal Medicine, 12/18/09

Zigzagged Augmentation Index in Diabetes
Clinical and Experimental Hypertension, 12/18/09

Does Decreased Diastolic Blood Pressure Associate with Increased Mortality in 80-Year-Old Japanese
Clinical and Experimental Hypertension, 12/18/09

 See all of Hypertension